PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue15,62211,69869,4298,676
Cost of Revenue----
Gross Profit15,62211,69869,4298,676
Operating Expenses
Research Development33,14740,58935,26928,196
Selling General and Administrative31,43126,90925,65618,184
Non Recurring----
Others----
Total Operating Expenses64,57867,49860,92546,380
Operating Income or Loss-48,956-55,8008,504-37,704
Income from Continuing Operations
Total Other Income/Expenses Net-20,333-6,8854,073-1,548
Earnings Before Interest and Taxes-48,956-55,8008,504-37,704
Interest Expense-5,000-5,100-493-493
Income Before Tax-69,289-62,68512,577-39,252
Income Tax Expense-1,632-11,6721,844-133
Minority Interest---205
Net Income From Continuing Ops-67,657-51,01310,733-39,119
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-67,657-51,01310,806-39,112
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-67,657-51,01310,806-39,112